Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies

Wandeler, GillesGillesWandelerKeiser, OliviaOliviaKeiser0000-0001-8191-2789Mulenga, LloydLloydMulengaHoffmann, Christopher JChristopher JHoffmannWood, RobinRobinWoodChaweza, ThomThomChawezaBrennan, AlanaAlanaBrennanProzesky, HansHansProzeskyGarone, DanielaDanielaGaroneGiddy, JanetJanetGiddyChimbetete, CleophasCleophasChimbeteteBoulle, AndrewAndrewBoulleEgger, MatthiasMatthiasEgger0000-0001-7462-5132IeDEA Southern Africa Collaboration2024-10-112024-10-112012https://boris-portal.unibe.ch/handle/20.500.12422/84026Tenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of South Africa (RSA).en600 - Technology::610 - Medicine & healthTenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studiesarticle10.7892/boris.139562274359500030835200001210.1097/QAI.0b013e3182632540